Advertisement
Advertisement
U.S. Markets open in 5 hrs 22 mins
Advertisement
Advertisement
Advertisement
Advertisement

Jupiter Wellness, Inc. (JUPW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7622-0.0477 (-5.89%)
At close: 04:00PM EST
0.7631 +0.00 (+0.12%)
After hours: 05:41PM EST
Advertisement
Sign in to post a message.
  • A
    Ajaz
    Is it a good buy now??
  • J
    Joe Ward
    How are we doing today
  • R
    Ree
    Is this a good buy now at this level or wait more ?
  • F
    Francis
    $JUPW $IRNT $OTRK $MARK All in A/H’s ready for some short squeezes tomorrow 🤑🤑🤑
    Bullish
  • S
    StockBard
    $OTRK 2 catalysts coming (Qtr Earnings Friday and Credit Suisse Conference Tuesday)
    Outstanding 19.15M
    Float 8.3M
    Short Interest 29.71% ~ 33.16%
    % Insiders own 55.72%
    % Institutions own 30.80%
    52 Week Range $8.46 - $99.89

    All Analysts have this as a strong buy and heavily oversold with fair price value of $16-$22.

    Smells like a squeeze 👏👏👏

    Also in $IRNT $JUPW as well
    Bullish
  • J
    Jose V
    New Release

    JUPITER, FL / November 11, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing cannabinoid receptor agonists for the treatment of eczema, actinic keratosis, burns, and herpes cold sores, announced that it has received an official written response from a Type B pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) for JW-100, a topical drug the treatment of eczema.

    The main purpose of the pre-IND meeting was to evaluate the drug development plan for JW-100.

    Jupiter Wellness believes that the written response from the FDA supports the Company’s approach and its overall drug development strategy to enable the filing of an IND for its clinical studies on JW-100.

    Dr. Glynn Wilson, Chief Scientific Officer of Jupiter Wellness, stated, “The pre-IND meeting written response marks an important milestone in the development of JW-100 for the treatment of eczema. We have obtained FDA concurrence and clear guidance on the proposed manufacturing, nonclinical pharmacology, and toxicology studies, and the Phase 1 clinical design.”

    JW-100 met its primary endpoint in a recently completed Phase 1-equivalent international study in which Jupiter’s topical formulation cleared or reduced eczema following two weeks of use. These results suggest JW-100 may potentially prove superior to existing prescription drugs for the treatment of eczema in future clinical trials. The global eczema treatment market is valued at $10 billion and expected to grow at a CAGR of 13% from 2020-2025.
  • R
    Russ
    In at $2.02
    Bullish
  • J
    Joe Ward
    Buying
  • T
    Thomas
    10 dollars soon
  • W
    William
    7 dollars/ in February
  • A
    Alan
    Full-time employees: 5 lol
    Bearish
  • D
    Dennis
    This name could very well catch on. In the afternoon, when the Reddit crowd wakes up to this, it could catch on fire... Also, there is, in fact, a good reason for it to spike...
  • J
    Jose V
    News Release

    Jupiter Wellness Announces Multi-Year Distribution Agreement with Rigour International for Expansion in Asia
    Bullish
  • b
    beam_me_up_pls
    $GTE conversation
    Top percent stock gainers for Tues. (GTE made it)
    $BTBT
    $ZETA
    $MARPS
    $JUPW
    $GTE
  • M
    May
    so they buying justCBD
    that's a game changer if true
  • b
    bseae
    Any body here..
  • C
    Christian
    What is the redemption info for the warrants?
  • H
    Harry
    10+ this week
  • A
    AaronJ
    Update from 10/19 up 10.44% and appears to be ready to run.
    Bullish
  • J
    Joe Ward
    Anything negative is a short anything positive a bag holder. Normal
Advertisement
Advertisement